Impact of bariatric surgery on type 2 diabetes

Luigi Fernando Meneghini

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The management and prevention of diabetes through lifestyle modifications and weight loss should be the mainstay of therapy in appropriate candidates. Although the results from the Diabetes Prevention Trial and the Finnish Prevention Study support this approach, over 95% of patients not participating in a prevention research study are unable to achieve and maintain any significant weight loss over time. Bariatric surgery for weight loss is an emerging option for more sustainable weight loss in the severely obese subject, especially when obesity is complicated by diabetes or other co-morbidities. The two most common types of procedures currently used in the United States are adjustable gastric bands and Roux-en-Y gastric bypass. These procedures can be performed laparoscopically, further reducing the perioperative morbidity and mortality associated with the surgery. While the gastric bypass procedure usually results is greater sustained weight loss (40-50%) than adjustable gastric banding (20-30%), it also carries greater morbidity and nutritional/metabolic issues, such as deficiencies in iron, B12, calcium, and vitamin D. Following bariatric surgery most subjects experience improvements in diabetes control, hypertension, dyslipidemia, and other obesity-related conditions. In patients with impaired glucose tolerance most studies report 99-100% prevention of progression to diabetes, while in subjects with diabetes prior to surgery, resolution of the disease is reported in 64-93% of the cases. While improvements in insulin resistance and beta-cell function are related to surgically induced weight loss, the rapid post-operative improvement in glycemia is possibly due to a combination of decreased nutrient intake and changes in gut hormones as a result of the bypassed intestine. Post-prandial hyperinsulinemic hypoglycemia associated with nesidioblastosis has been described in a series of patients following gastric bypass surgery, and may be related to the described changes in GLP-1 and other gut hormones.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalCell Biochemistry and Biophysics
Volume48
Issue number2-3
DOIs
StatePublished - Jun 1 2007

Fingerprint

Bariatric Surgery
Medical problems
Surgery
Type 2 Diabetes Mellitus
Weight Loss
Gastric Bypass
Morbidity
Stomach
Nesidioblastosis
Obesity
Hormones
Glucagon-Like Peptide 1
Glucose Intolerance
Dyslipidemias
Hypoglycemia
Vitamin D
Nutrients
Intestines
Meals
Insulin Resistance

Keywords

  • Bariatric surgery
  • Diabetes
  • Gastric banding
  • Gastric bypass
  • Glucagon-like Peptide 1 (GLP-1)
  • Impaired glucose tolerance
  • Weight loss

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Biophysics
  • Biochemistry

Cite this

Impact of bariatric surgery on type 2 diabetes. / Meneghini, Luigi Fernando.

In: Cell Biochemistry and Biophysics, Vol. 48, No. 2-3, 01.06.2007, p. 97-102.

Research output: Contribution to journalArticle

Meneghini, Luigi Fernando. / Impact of bariatric surgery on type 2 diabetes. In: Cell Biochemistry and Biophysics. 2007 ; Vol. 48, No. 2-3. pp. 97-102.
@article{ca04941aeafe4254965ed3f13b814cf5,
title = "Impact of bariatric surgery on type 2 diabetes",
abstract = "The management and prevention of diabetes through lifestyle modifications and weight loss should be the mainstay of therapy in appropriate candidates. Although the results from the Diabetes Prevention Trial and the Finnish Prevention Study support this approach, over 95{\%} of patients not participating in a prevention research study are unable to achieve and maintain any significant weight loss over time. Bariatric surgery for weight loss is an emerging option for more sustainable weight loss in the severely obese subject, especially when obesity is complicated by diabetes or other co-morbidities. The two most common types of procedures currently used in the United States are adjustable gastric bands and Roux-en-Y gastric bypass. These procedures can be performed laparoscopically, further reducing the perioperative morbidity and mortality associated with the surgery. While the gastric bypass procedure usually results is greater sustained weight loss (40-50{\%}) than adjustable gastric banding (20-30{\%}), it also carries greater morbidity and nutritional/metabolic issues, such as deficiencies in iron, B12, calcium, and vitamin D. Following bariatric surgery most subjects experience improvements in diabetes control, hypertension, dyslipidemia, and other obesity-related conditions. In patients with impaired glucose tolerance most studies report 99-100{\%} prevention of progression to diabetes, while in subjects with diabetes prior to surgery, resolution of the disease is reported in 64-93{\%} of the cases. While improvements in insulin resistance and beta-cell function are related to surgically induced weight loss, the rapid post-operative improvement in glycemia is possibly due to a combination of decreased nutrient intake and changes in gut hormones as a result of the bypassed intestine. Post-prandial hyperinsulinemic hypoglycemia associated with nesidioblastosis has been described in a series of patients following gastric bypass surgery, and may be related to the described changes in GLP-1 and other gut hormones.",
keywords = "Bariatric surgery, Diabetes, Gastric banding, Gastric bypass, Glucagon-like Peptide 1 (GLP-1), Impaired glucose tolerance, Weight loss",
author = "Meneghini, {Luigi Fernando}",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/s12013-007-0020-y",
language = "English",
volume = "48",
pages = "97--102",
journal = "Cell Biochemistry and Biophysics",
issn = "1085-9195",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Impact of bariatric surgery on type 2 diabetes

AU - Meneghini, Luigi Fernando

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The management and prevention of diabetes through lifestyle modifications and weight loss should be the mainstay of therapy in appropriate candidates. Although the results from the Diabetes Prevention Trial and the Finnish Prevention Study support this approach, over 95% of patients not participating in a prevention research study are unable to achieve and maintain any significant weight loss over time. Bariatric surgery for weight loss is an emerging option for more sustainable weight loss in the severely obese subject, especially when obesity is complicated by diabetes or other co-morbidities. The two most common types of procedures currently used in the United States are adjustable gastric bands and Roux-en-Y gastric bypass. These procedures can be performed laparoscopically, further reducing the perioperative morbidity and mortality associated with the surgery. While the gastric bypass procedure usually results is greater sustained weight loss (40-50%) than adjustable gastric banding (20-30%), it also carries greater morbidity and nutritional/metabolic issues, such as deficiencies in iron, B12, calcium, and vitamin D. Following bariatric surgery most subjects experience improvements in diabetes control, hypertension, dyslipidemia, and other obesity-related conditions. In patients with impaired glucose tolerance most studies report 99-100% prevention of progression to diabetes, while in subjects with diabetes prior to surgery, resolution of the disease is reported in 64-93% of the cases. While improvements in insulin resistance and beta-cell function are related to surgically induced weight loss, the rapid post-operative improvement in glycemia is possibly due to a combination of decreased nutrient intake and changes in gut hormones as a result of the bypassed intestine. Post-prandial hyperinsulinemic hypoglycemia associated with nesidioblastosis has been described in a series of patients following gastric bypass surgery, and may be related to the described changes in GLP-1 and other gut hormones.

AB - The management and prevention of diabetes through lifestyle modifications and weight loss should be the mainstay of therapy in appropriate candidates. Although the results from the Diabetes Prevention Trial and the Finnish Prevention Study support this approach, over 95% of patients not participating in a prevention research study are unable to achieve and maintain any significant weight loss over time. Bariatric surgery for weight loss is an emerging option for more sustainable weight loss in the severely obese subject, especially when obesity is complicated by diabetes or other co-morbidities. The two most common types of procedures currently used in the United States are adjustable gastric bands and Roux-en-Y gastric bypass. These procedures can be performed laparoscopically, further reducing the perioperative morbidity and mortality associated with the surgery. While the gastric bypass procedure usually results is greater sustained weight loss (40-50%) than adjustable gastric banding (20-30%), it also carries greater morbidity and nutritional/metabolic issues, such as deficiencies in iron, B12, calcium, and vitamin D. Following bariatric surgery most subjects experience improvements in diabetes control, hypertension, dyslipidemia, and other obesity-related conditions. In patients with impaired glucose tolerance most studies report 99-100% prevention of progression to diabetes, while in subjects with diabetes prior to surgery, resolution of the disease is reported in 64-93% of the cases. While improvements in insulin resistance and beta-cell function are related to surgically induced weight loss, the rapid post-operative improvement in glycemia is possibly due to a combination of decreased nutrient intake and changes in gut hormones as a result of the bypassed intestine. Post-prandial hyperinsulinemic hypoglycemia associated with nesidioblastosis has been described in a series of patients following gastric bypass surgery, and may be related to the described changes in GLP-1 and other gut hormones.

KW - Bariatric surgery

KW - Diabetes

KW - Gastric banding

KW - Gastric bypass

KW - Glucagon-like Peptide 1 (GLP-1)

KW - Impaired glucose tolerance

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=34548321630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548321630&partnerID=8YFLogxK

U2 - 10.1007/s12013-007-0020-y

DO - 10.1007/s12013-007-0020-y

M3 - Article

VL - 48

SP - 97

EP - 102

JO - Cell Biochemistry and Biophysics

JF - Cell Biochemistry and Biophysics

SN - 1085-9195

IS - 2-3

ER -